Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2014 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March

WELLESLEY, MA--(Marketwired - Mar 26, 2014) - Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company"), a life sciences...
February 26, 2014 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference

WELLESLEY, MA--(Marketwired - Feb 26, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
February 10, 2014 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Secures $2.85 Million Private Placement

WELLESLEY, MA--(Marketwired - Feb 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
January 31, 2014 06:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces $2.85 Million Private Placement

WELLESLEY, MA--(Marketwired - Jan 31, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
January 22, 2014 11:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Presents 2014 Milestones During Live Webcast

WELLESLEY, MA--(Marketwired - Jan 22, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
January 14, 2014 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference

WELLESLEY, MA--(Marketwired - Jan 14, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a...
January 08, 2014 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference

WELLESLEY, MA--(Marketwired - Jan 8, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5™, a novel product aimed at...
October 10, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Co-Founder Dr. Ellis-Behnke to Speak at Nanomanufacturing Summit 2013 in Philadelphia, October 15, 2013

WELLESLEY, MA--(Marketwired - Oct 10, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), is pleased to announce that co-founding and inventing scientist, Dr. Rutledge...
October 07, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Approval of $1 Million Massachusetts Life Sciences Center Accelerator Loan

WELLESLEY, MA--(Marketwired - Oct 7, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences company and developer of AC5™, a novel product aimed at...
September 20, 2013 09:00 ET | Source: Arch Therapeutics, Inc.

Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27

CAMBRIDGE, MA--(Marketwired - Sep 20, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will be featured as a presenting company at the Boulder Peptide...